December 6, 2017 07:28 AM EST
Bioregnum
Opinion

Af­ter build­ing ex­pec­ta­tions, the UK’s life sci­ences plan falls short of the hype

Mer­ck’s re­cent an­nounce­ment of a new re­search cen­ter in Lon­don like­ly whet­ted the UK life sci­ences sec­tor’s ap­petite for even big­ger news from the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times